Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic kidney disease?;¿Existe relación entre los niveles de cistatina C y el estado inflamatorio, el estrés oxidativo y otros factores de riesgo cardiovascular en pacientes no diabéticos con enfermedad renal crónica?

Nefrologia

Volumn 29, Issue 3, 2009, Pages 228-235

  Font, R ^a   Prats, M ^a   Gutierrez C ^b   Bardaji A ^c   Lalana, M ^d   Marsillach, J ^e   Camps, J ^e   Martinez Vea A ^a  

^a Servicio de Nefrología   (Spain)

^b Servicio de Medicina Interna   (Spain)

^c Servicio de Cardiología   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^e HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Chronic kidney disease; Cystatin C.; Inflammation; Oxidative stress; Paraoxonase 1; Risk factors

Indexed keywords

CYSTATIN C;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFLAMMATION; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; HUMANS; INFLAMMATION; KIDNEY DISEASES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 70349237271     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/NEFROLOGIA.2009.29.3.5242.EN.FULL     Document Type: Article

References (50)

1. Tenstad O, Roald AB, Grubb A, Auckland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996;56:409-14.
2. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001;37:79-83.
3. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduce glomerular filtration rate. Am J Nephrol 2000;20:97-102.
4. Jernberg T, Lindahal B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-8.
5. Shilpak MG, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and mortality in elderly persons with heart failure, J Am Coll Cardiol 2005;45:268-71.
6. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-60.
7. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick DS, Schlipak MG. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142:497-505.
8. Shlipak MG, Wassel FCL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al. Cystatin C and mortality risk in the elderly: The health, aging and body composition study. J Am Soc Nephrol 2006;17:254-61.
9. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-46.
10. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007;147:19-27.
11. Newman DJ, Takkar H, Edwards RG, Wlikie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-8.
12. Coll E, Botey A, Álvarez L, Poch E, Quinto L, Taurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000;36:29-34.
13. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-21.
14. Köttgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008;51:385-94.
15. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, Barron J, Lemmey A. GFR estimation using Cystatin C is not independent of body composition. Am J Kidney Dis 2006;48:712-9.
16. De Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the Multi-Ethnic study of atherosclerosis. Clin J Am Soc Nephrol 2008;3:125-32.
17. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Bagnis CI. Is serum cystatin C a reliable marker for metabolic syndrome? Am J Med 2008; 121:426-32.
18. Peralta CA, Whooley MA, Ix JH, Shlipak MG. Kidney function and systolic blood pressure. New insights from cystatin C: Data from the Heart and Soul Study. Am J Hypertens 2006;19.939-46.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-536.
20. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:261-8.
21. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995,15:1812-8.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
23. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II system. Scand J Clin Lab Invest 1999;59:1-8.
24. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
25. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in men: anatomic validation of the method. Circulation 1977;55:613-8.
26. De Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Strong Heart Study Investigators. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Stydy. Am J Hypertens 2005;18:191-6.
27. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, et al. Cystatin C and inflammatory markers in the ambulatory elderly. Am J Med 2005;118:1416.e25-1416.e31.
28. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: The Health, aging and body composition study. Kidney Int 2007;71:239-44.
29. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: The Heart and Sould Study. Nephrol Dial Transplant 2007;22:1087-92.
30. Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Low-gra-de inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. Clin Nephrol 2007;68:1-9.
31. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-36.
32. Landray MJ, Wheeler DC, Lip GYH, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activitation in patients with chronic kidney disease: The Chronic Renal Impairment in Birmingham(CRIB) Study. Am J Kidney Dis 2004;43:244-53.
33. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-16.
34. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68:766-72.
35. Annuk M, Fellström B, Akerblom O, Zilmer K, Vihalemn T, Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol 2001;56:308-14.
36. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease. An emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272-80.
37. Vaziri ND. Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Semin Nephrol 2004;25:469-73.
38. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized lowdensity lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8.
39. Shoji T, Fukumoto M, Kimono E, Shinohara K, Emoto M, Tahara H, et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002;62:2230-7.
40. Maggi E, Bellazi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-76.
41. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al. The determinants of endotelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2005;47:42-50.
42. Watson AD, Berliner JA, Hama SY, LaDu BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
43. Paragh G, Seres I, Valgo Z, Varga Z, Kárpáti I, Mátyus J, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-70.
44. Paragh G, Asztalos L, Seres I, Valgo Z, Löcsey L, Kárpáti I, et al. Serum paraoxonase activity changes in uremia and kidney-transplanted patients. Nephron 1999;83:126-31.
45. Suehiro T, Ikeda Y, Shiinoki T, Inoue M, Kumon Y, Tiara T, et al. Serum paraoxonase(PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002;9:133-8.
46. Ikeda Y, Suehiro T, Tiara T, INRI Y, Chikazawa H, Inoue M, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67:358-65.
47. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 2003;26:895-9.
48. Prats M, Font R, Bardají A, Gutiérrez C, Lalana M, Vilanova A, et al. Cystatin C, cardiac hypertrophy and diastolic dysfunction in hypertensive patients with normal renal function. Rev Esp Cardiol (in press).
49. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy and diastolic dysfunction: data from the Heart and Soul Study. J Cardiac Fail 2006;12:601-7.
50. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.